Sana Biotechnology focuses on creating and delivering engineered cells as medicines, with programs aimed at modulating genes in cells and replacing damaged cells. The company’s core platforms include gene delivery, immunology, stem cell biology, and gene modification and control. Approaches described include in vivo delivery of genetic payloads to specific cells, ex vivo genetic modifications to hide allogeneic cells from a patient’s immune system, and using stem cell biology to make differentiated cells to replace missing or damaged tissue. Proceeds from the financing are expected to support IND-enabling and initial clinical studies for multiple therapeutic candidates, buildout of manufacturing capabilities, and expansion of the company’s portfolio of enabling technologies. The company said funding will also support continued addition of top talent to its team; Sana reports a team of 200+ scientists, engineers, clinicians and biotechnology veterans. Sana has operations in Seattle, Cambridge, and South San Francisco.

Total raised

$700M

Funding rounds

1

Latest round

Equity

Latest activity

Jun 2020